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Abstract
Background: Mutations in the PYGM gene encoding skeletal muscle glycogen phosphorylase (GP) cause a metabolic
disorder known as McArdle’s disease. Previous studies in muscle biopsies and cultured muscle cells from McArdle patients
have shown that PYGM mutations abolish GP activity in skeletal muscle, but that the enzyme activity reappears when
muscle cells are in culture. The identification of the GP isoenzyme that accounts for this activity remains controversial.
Methodology/Principal Findings: In this study we present two related patients harbouring a novel PYGM mutation,
p.R771PfsX33. In the patients’ skeletal muscle biopsies, PYGM mRNA levels were ,60% lower than those observed in two
matched healthy controls; biochemical analysis of a patient muscle biopsy resulted in undetectable GP protein and GP
activity. A strong reduction of the PYGM mRNA was observed in cultured muscle cells from patients and controls, as
compared to the levels observed in muscle tissue. In cultured cells, PYGM mRNA levels were negligible regardless of the
differentiation stage. After a 12 day period of differentiation similar expression of the brain and liver isoforms were observed
at the mRNA level in cells from patients and controls. Total GP activity (measured with AMP) was not different either;
however, the active GP activity and immunoreactive GP protein levels were lower in patients’ cell cultures. GP
immunoreactivity was mainly due to brain and liver GP but muscle GP seemed to be responsible for the differences.
Conclusions/Significance: These results indicate that in both patients’ and controls’ cell cultures, unlike in skeletal muscle
tissue, most of the protein and GP activities result from the expression of brain GP and liver GP genes, although there is still
some activity resulting from the expression of the muscle GP gene. More research is necessary to clarify the differential
mechanisms of metabolic adaptations that McArdle cultures undergo in vitro.
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Introduction
Glycogen phosphorylase (GP) is a finely regulated key enzyme
in the metabolism of glycogen. Its 1,4-a-glucan-phosphate-
glucosyltransferase activity catalyzes a limiting step in glycogen-
olysis, i.e. glycogen phosphorolysis to form glucose-1-P [1]. There
are three different GP isoenzymes encoded by three different
genes, apparently evolved from a common ancestral gene, i.e.
PYGB (brain) PYGL (liver), and PYGM (skeletal muscle) [2].
In 1959, lack of muscle GP was identified as the cause of a
glycogenolytic defect confined to the skeletal muscles [3,4]. The
clinical features of this disorder, known as McArdle’s disease or
glycogenolysis type V had first been described a few years earlier
by Brian McArdle [5], and encompass exercise intolerance with
reversible acute crises of premature fatigue, myalgia and
contractures, sometimes accompanied by severe rhabdomyolysis
and myoglobinuria; these episodes are triggered by static or
isometric muscle contractions as well as by dynamic, strenuous
exercises such as running [6].
Since the publication of the first pathogenic PYGM mutations in
1993 [7,8], a growing allelic heterogeneity of the PYGM gene has
been reported, with more than 100 mutations known to cause
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McArdle’s disease [9]. A stop-codon mutation, p.R50X, is
commonly encountered in European and American patients with
an allelic frequency ranging from 81% to 43% in different
populations. However, most mutations are private, i.e. reported in
a single patient or in the members of the same family [9].
Moreover, studies on skeletal muscle cDNA resulted in: (i) the
identification of mutations that genomic direct analysis failed to
detect, and (ii) understanding the effect of PYGM mutations in
gene expression [10]. An RNA surveillance mechanism known as
‘nonsense mediated mRNA decay’ (NMD), reduces the mRNA
levels of those transcripts that contain nonsense and frameshift
mutations [11]. Our previous results support the notion that NMD
is a common acting mechanism among McArdle patients, with
92% of them showing a reduced amount of PYGM mRNA levels
[12].
GP activity in muscle biopsies and cultured muscle cells from
McArdle patients has previously been studied. No detectable GP
activity is observed in muscle biopsies from patients; however,
cultured muscle cells derived from the same biopsies did present
GP activity [13,14,15,16]. It has also been described in
regenerative fibers from McArdle patients [17]. This phenomenon
was described as ‘‘the mystery of the reappearing enzyme’’
[17,18], although it is not clear which specific GP isoform accounts
for this activity, i.e. brain isoform [15], brain and liver isoform [16]
vs. skeletal muscle isoform [13,14].
In this study we have characterized the molecular alterations
produced by a novel frameshift PYGM mutation (p.R771PfsX33), at
the mRNA and protein levels, in the skeletal muscle biopsy of two
related McArdle patients. In addition, we also cultured skeletal
muscle cells, determined the expression of the different GP
isoforms, and characterized the glycogen metabolism by deter-
mining GP activity, glycogen synthase (GS) activity and glycogen
content.
Methods
Ethics Statement
Written informed consent was obtained from all individuals.
The study was approved by the institutional review board of the
University Hospital 12 de Octubre and was carried out in
accordance with the Declaration of Helsinki for Human Research.
Subjects
We report two Caucasian brothers (index case P1, and P2), aged
43 and 51 years, from a small village in southern Spain, with
family history of consanguinity but not of neuromuscular diseases.
They both presented the four cardinal features of the disease [6]:
(i) exercise intolerance since childhood; (ii) high serum levels of
creatine kinase (CK) activity, even in basal conditions (672 U?l21
and 344 U?l21 at the moment of study, after 2 resting days,
normal ,170 U?l21); (iii) previous episodes of hyper-CK-emia
(,7,000 and 10,000 U?l21) plus myoglobinuria after intense
exercise, indicating marked rhabdomyolysis; and (iv) the ‘second
wind’ phenomenon, depicted by a sudden, marked improvement
tolerance to aerobic dynamic exercise (notably, brisk walking) after
,8–10 minutes of exercise or after a short period of rest [19].
Their peak oxygen uptake (VO2peak) measured during incremental
cycle-ergometer testing was very low (12.5 and 13.0 ml O2/kg/
min), barely above the limits for independent living, which reflects
a markedly decreased muscle oxidative capacity, another common
feature of the disease [20]. Two sex- and age-matched healthy
Spanish volunteers recruited for the study (C1, C2) served as
controls (Table 1). Their VO2peak was 36 and 38 ml O2/kg/min.
Biochemical and genetic analyses
McArdle’s disease was suspected on clinical bases in the index
case (P1). A muscle biopsy was obtained to assess glycogen
phosphorylase activity, which was undetectable. Thus, the
diagnosis was confirmed genetically by PYGM sequencing in P1
and his brother (P2), who was also clinically affected (see above).
PYGM gene was sequenced as follows: DNA was isolated from
whole blood using a standard phenol-chloroform method
(Nucleon BACC-2, GE healthcare Europe GMBH, Chalfont St.
Giles, UK). We amplified the coding sequence of the entire PYGM
gene by polymerase chain reaction (PCR) in 14 fragments, using
the primers described by Kubisch et al [21]. For PCR analysis and
sequencing, we followed the steps described elsewhere [22]. In
order to perform a more exhaustive screening, we performed
PYGM amplification of cDNA samples (see below), with a different
set of primers [12].
Muscle samples
We obtained a biceps biopsy from P1 for diagnostic purposes (GP
activity assessment) and immunoblotting. Once McArdle’s disease
was confirmed, a new biceps biopsy was obtained from P1, as well
as from P2, C1 and C2, for research purposes. Each biopsy
specimen was divided in two fragments, for myoblast isolation and
for RNA extraction.
Muscle cell culture, immunohistochemistry and electron
microscopy
Myoblast cell populations were isolated from muscle biopsies
using the explant culture technique [23]. Myoblasts were grown in
DMEM/M-199 medium, 3:1, with 10% fetal bovine serum (FBS),
10 mg/ml insulin, 2 mM glutamine, 25 ng/ml fibroblast growth
factor and 10 ng/ml epidermal growth factor. Confluent cells were
induced to differentiate for 7 or 12 days by removing fibroblast and
epidermal growth factors. Twenty-four hours before the metabolic
experiments, cells were depleted of insulin and FBS. For
immunohistochemistry analyses, cells grown on coverslips were
fixed in 4% paraformaldehyde in PBS, then washed with PBS
followed by 3 sequential treatments with PBS containing: (1)
20 mM glycine, (2) 0.1% Triton X-100 and (3) 1% BSA. Next,
coverslips were incubated with a rabbit anti-desmin antibody
(AB907 Millipore, Billerica, MA, USA). The primary antibody was
detected with an Alexa Fluor-488 goat anti-rabbit antibody
(Molecular Probes, Eugene, OR, USA). Both primary and
secondary antibodies were diluted in blocking solution. Nuclei were
stained with Hoescht (1 mg/ml) after secondary antibody incuba-
tion. After staining, samples were mounted and analyzed with a
Leica TCS SP2 confocal microscope. For electron microscopy, cells
were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (PB)
(pH 7.4), then cells were scraped in PB and post-fixed with 1%
Table 1. Subjects’ information.
Subject Age* Sex PYGM genotype PYGM mRNA (%)
P1 44 Male p.R771PfsX33/p.R771PfsX33 40
P2 55 Male p.R771PfsX33/p.R771PfsX33 32
C1 43 Male wild type/wild type 94
C2 46 Male wild type/wild type 107
*Age at the time the skeletal muscle biopsy was collected. GenBank reference
sequence was NP_005600.1. Expression values were calculated considering
100% the mean results obtained in the controls (C1, C2).
doi:10.1371/journal.pone.0013164.t001
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osmium tetroxide in PB containing 0.8% potassium ferricyanide at
4uC. Then cells were dehydrated in acetone, infiltrated in Epon
resin for 2 days, embedded in the same resin and polymerised at
60uC during 48 h. Ultrathin sections were obtained using a Leica
Ultracut UCT ultramicrotome and mounted on Formvar-coated
cooper grids. They were stained with 2% uranyl acetate in water
and lead citrate. Then sections were observed in a JEM-1010
electron microscope (Jeol, Tokyo, Japan). The diameter size of
glycogen granules was measured with AnalySIS (Soft Imaging
System, Olympus, Hamburg, Germany). The amount and diameter
of glycogen particles weremeasured in images of myotubes obtained
at x 30,000 magnification. Five cells from C1 and P1 and three
different cell areas per cell were examined.
cDNA synthesis
Total RNA was extracted from the biopsies and cultured cells
using TrizolH reagent (Invitrogen, Carlsbad, USA). To eliminate
any traces of DNA, RNA was treated with the DNAse I,
amplification grade (Invitrogen, Carlsbad, USA). The RNA
concentration and quality was measured with NanoChips, using
the Boanalyzer 2100 system and the 2100 Expert Software version
B.02.02 (Agilent, Santa Clara, USA). cDNA was synthesized from
muscle RNA using the high-capacity cDNA archive kit (Applied
Biosystems, Foster City, USA), which uses random primers.
Real Time PCR analysis
GP mRNA levels were quantified by real-time PCR, using
TaqMan fluorogenic probes in a 7,500 Real Time PCR System
(Applied biosystems, Foster City, USA). We used a probe located
in exons 6–7 for the detection of PYGM mRNA
(Hs00194493_m1), a probe located in exons 5–6 for PYGB mRNA
(Hs00267875_m1), and a probe located in exons 3–4 for PYGL
mRNA (Hs00161132_m1). Results were normalized to cyclophilin
A (PPIA) mRNA levels (probe Hs0099999904_m1). The real time
PCR was performed as described elsewhere [12]. When
comparing gene expression levels between C2 skeletal muscle
biopsy specimen and its corresponding cell culture, we used the
amount of total RNA per well to normalize the results. Similar
efficiencies of amplification were observed for the PGYM, PYGB,
PYGL and PPIA cDNAs.
Enzyme activity and glycogen assays
GP activity was measured in the muscle biopsy of patient P1
following the standard procedure [24]. In order to measure GS and
GP activities in the cultured cells, we used 100 ml of homogenization
buffer (10 mM Tris-HCl pH 7.0, 150 mM KF, 15 mM EDTA,
600 mM sucrose, 15 mM 2-mercaptoethanol, 17 mg/l leupeptin,
1 mM benzamidine and 1 mM phenylmethylsulfonyl fluoride) to
scrape frozen plates containing the cell monolayers prior to
sonication. The homogenates were used to determine enzyme
activities. GP activity was determined by the incorporation of
[U-14C] glucose 1-phosphate into glycogen in the absence (activated
GP) or presence (total GP) of the allosteric activator AMP (1 mM)
[25]. GS activity was measured in the absence (activated GS) or
presence (total GS) of 10 mM glucose 6-P as described [26].
Aliquots of the homogenates were used to measure protein
concentration. Glycogen was extracted from cell monolayers as
previously described [27] and released glucose quantified with the
Glucose (HK) assay kit (Sigma Aldrich, Saint Louis, USA).
Immunoblotting analysis
Skeletal muscle biopsies were homogenated in 50 mM Tris-HCl
pH 7.5, 150 mM NaCl and 1% SDS. Cell extracts prepared as
described above were mixed 1:1 with a homogenization buffer
consisting of 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM
Na3VO4, 2 mg/ml benzamidine, 2 mg/ml leupeptin, 1% (v/v)
Nonidet P40, and 1 mM dithiothreitol. Lysates were then gently
rocked for 60 min at 4uC, and stored at 280uC until analysis.
Protein was resolved in 10% SDS-PAGE. Antibodies against
muscle GS (3893, Cell Signaling, Danvers, USA), brain/muscle
GP (4GP31/17B6, HyTest, Turku, Finland), muscle GP in biopsy
(AB63158, Abcam, Cambridge, UK) and for muscle GP in cell
cultures (LS-A2284 MBL International Corporation, Woburn,
USA), brain GP (BB-1F9:SC-81751, Santa Cruz Biotechnology,
CA, USA) and liver GP (HPA000962, Sigma, St. Louis, USA)
were utilized. Horseradish peroxidase-conjugated secondary
antibodies were used and membranes were developed with
ECL-Plus (GE Healthcare, Buckinghamshire, England). Bands
were obtained with a LAS-3000 (FujiFilm, Tokyo, Japan) and
quantified with NIH image J, version 1.37 analysis software (Scion
image, NIH). a-Actin (C-terminal anti-actin antibody, Sigma,
Saint Louis, USA) and a-tubulin (Sigma, Saint Louis, USA) were
used as housekeeping proteins.
Statistical analysis
We performed all statistical analysis with the SPSS package
(SPSS 12.0, Chicago, IL, USA). The Mann Whitney’s U test was
used to analyze differences between the two groups (patients and
controls).
Results
Genetic analysis
Sequencing of the PCR products spanning the entire PYGM
gene coding region revealed the presence of a homozygous CC
duplication in the exon 18 (c.2310_2311dupCC) in both patients
(Figure 1A). This mutation changes arginine to proline in the
position 771 of the protein and alters the open reading frame
predicting a premature stop codon 33 amino acid residues
downstream (p.R771PfsX33). No other mutations were found in
the coding sequence or flanking intronic regions of the PYGM
gene, nor in the cDNA. The nomenclature of the mutation is
referred to the GenBank entries NM_005609.1 (cDNA) and
NP_005600.1 (protein).
Differential expression of GP genes in skeletal muscle
and cultured cells
Total GP activity was measured in skeletal muscle biopsy from
patient P1 and was undetectable. GP activity was not analyzed in
P2 muscle because the diagnostic was confirmed in P2 by PYGM
gene sequencing. Muscle PYGM mRNA levels of P1 and P2 were
reduced to 40% and 32% respectively, as compared to the mean of
C1 and C2 PYGM mRNA levels (Table 1). A specific antibody
against muscle GP was used to detect this isoform in C1 and P1
muscle homogenates, resulting in the expected 97 kDa muscle GP
band in C1, which was absent in P1 (Figure 1B).
While virtually all the mRNA found in C1 and C2 skeletal
muscle was the product of the expression of PYGM (.99%), this
gene poorly contributed (between 0.6 – 2.5%) to the total GP
mRNA in undifferentiated cultured cells, either from patients or
controls, and only reached moderate contribution (17%) in 12
days differentiated P2 cells (Figure 1C). When referred to total
RNA, PYGM mRNA levels were approximately 27-fold higher in
C2 muscle than in cultured cells. By contrast, PYGL mRNA was
17-fold higher in cultured cells, while PYGB mRNA levels were
similar in muscle tissue and cultured cells (data not shown). The
GP Isoforms in Cultured Muscle
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relative contribution of each gene (PYGB and PYGL) to the total
amount of GP mRNA in muscle, undifferentiated and differen-
tiated cultured cells was markedly different (Figure 1C). Before
differentiation, the major contributor in cell culture of C1, P1
and P2 was PYGB gene, while 12 days after differentiation both
PYGB and PYGL genes contributed equally to the total GP
mRNA pool in C1, C2 and P1, and moderately higher PYGB
mRNA was found in P2. However, no significant differences
between patients and controls were observed in the relative
contributions of each gene in cultured cells. Figure 2 shows the
changes in the mRNA levels, product from the three different
genes, over a period of differentiation of 12 days. The inspection
of the data did not show obvious differences in the distribution of
the mRNA levels between patients and controls for any of the
GP isoforms. Overall, PYGB mRNA had tendency to decrease
with the time in culture, while PYGL mRNA seemed to increase.
PYGM mRNA did not show a clear tendency, except for a
moderate increase in 12 day differentiated P2 cells. In absolute
amounts, this variation was low when compared to that observed
for PYGB and PYGL mRNAs, due to the minute amounts of
PYGM mRNA detected in cultured cells as compared to the
other isoforms.
Figure 1. Molecular effects of c.2310_2311dupCC mutation and GP isoforms expression in muscle cells. (A) Electropherogram of PYGM
exon 18 in control C1 (top) and patient P1 (bottom). The square shows the c.2310_2311dupCC mutation. Exonic nucleotides are underlined in black;
intronic nucleotides are underlined in grey. Encoded amino acids are indicated (including wild type Arg, and mutant Gly, encoded by codons formed
in an exon-exon junction). (B) Immunoblotting showing muscle GP and a-tubulin bands in muscle biopsy homogenates from control C1 and patient
P1. (C) Relative contribution of each gene (PYGM, PYGB and PYGL), to the total amount of GP mRNA in undifferentiated and 12 day differentiated
cultured muscle cells. Bars represent the result of a single experiment for undifferentiated cells, or mean6 SD of two independent experiments for 12
days differentiated cells. Percentages were calculated as [PYG(x) mRNA x 100/(PYGB mRNA + PYGL mRNA + PYGM mRNA)], using values normalized for
the PPIA mRNA. In C1 and C2 skeletal muscle (not shown), PYGB mRNA and PYGL mRNA were negligible (,0.5%).
doi:10.1371/journal.pone.0013164.g001
GP Isoforms in Cultured Muscle
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Cell morphology
Muscle cells were prevalent in the control C1 and patients P1
and P2 cultures as assessed by immunostaining for desmin, a
muscle-specific intermediate filament protein. As shown in
Figure 3, at day 7 post-differentiation, most of the Hoescht-
stained nuclei are observed in desmin-labeled cells. Noteworthy, in
cultures from patient P1, unfused mononucleated myoblasts were
abundant, whereas in control C1 and patient P2, myotubes
Figure 2. mRNA quantification of GP genes at 0, 7 and 12 days of differentiation. Results from a single experiment (before differentiation;
C1, P1 and P2), or mean of two independent experiments (7-day and 12-day differentiation, C1, C2, P1 and P2) are depicted.
doi:10.1371/journal.pone.0013164.g002
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prevailed. Cell morphology was similar at day 12 post-differen-
tiation, although muscle cells appeared less delineated in the three
cell cultures (data not shown).
Enzyme activities and glycogen content in the cell
cultures
We performed biochemical analyses of the cell cultures after 7
days of differentiation. No differences were found when comparing
the total activity of GP (controls 13668 munits/mg of protein and
patients 121612 munits/mg of protein) and GS (controls
22.062.5 munits/mg of protein and patients 20.461.6 munits/
mg of protein) between patients and controls. However, the active
forms of GP and GS activities were about 50% lower in the
patients’ cell cultures with statistical significance being reached
(p,0.05). Consequently, the GP and GS activity ratios (active/
total) (Figure 4) were also lower in the patients’ cell cultures. The
amount of glycogen in the patients’ cell lines was not significantly
different from that of control lines, although they had a tendency
to a lower glycogen concentration (Figure 4). Electron microscopic
evaluation of glycogen stores (Figure 5) showed that cells from
patient P1 had a significantly (p = 2.8661027) lower number of
glycogen granules per cell (45.91611.35) than control C1 cells
(153.0652.42), but slightly larger granules of glycogen
(27.1968.98 nm) than control C1 cells (25.4469.04 nm)
(p = 0.001). In both cell types, glycogen granules and small
glycogen clusters were scattered through the cytoplasm; addition-
ally glycogen accumulation in large multigranular bodies was
observed (not shown).
Immunoblotting analysis in the cell cultures
We determined the content of GP protein isoforms in the cell
cultures after 7 days of differentiation (Figure 6). First, the brain/
muscle GP protein level was assessed with an antibody that besides
the brain GP protein recognizes the muscle GP protein when
overexpressed in cultured myotubes [28]. We observed about 50%
lower levels of brain/muscle GP isoforms relative to a-actin
protein in the patients’ lines. No signal was however detected when
a muscle GP specific antibody was used (data not shown), likely
due to the very low gene expression levels, as previously observed
[28]. No statistically significant differences were detected when
using brain GP or liver GP specific antibodies relative to a-actin
protein, in either controls’ or patients’ cells, although a tendency to
increase was observed in patient’s cells. We found no significant
differences in muscle GS protein content with a rising tendency in
patient’s cells also.
Discussion
Allelic heterogeneity is a characteristic of PYGM genotypes in
McArdle patients, as many mutations are only found in a single
patient or in the members of the same family. Here, we have
identified the mutation p.R771PfsX33 in homozygosity in two
brothers with McArdle’s disease. This mutation alters the open
reading frame and generates a premature stop codon, which
predicts the loss of the final 72 amino acids of the C-terminal
domain. These include codons 824 and 825, strongly conserved in
14 GP enzymes from different species [1]. Other mutations
generating premature stop codons near codon 771 have been
reported to cause McArdle’s disease: p.E779delE, found in a
Korean patient [29], and p.C784X [22] and p.E797VfsX18 [30],
both described in Spanish patients. The new mutation reported
here should be added to the long list of pathogenic variations
described in the PYGM gene.
We recently demonstrated absence of PYGM transcripts in the
skeletal muscle of patients carrying nonsense and frameshift
mutations, most likely due to mRNA degradation induced by
NMD [12]. This is a critical process for normal cellular
Figure 3. Immunostaining of myotube cultures with the muscle-specific marker desmin. Myotubes at 7 days post-differentiation were
immunostained with desmin antibody and then cell nuclei were stained with Hoescht. Representative immunofluorescence micrographs of skeletal
muscle cultures are shown: (A,B,E,F) C1, (C,D) P1 and (G,H) P2. In A, C, E and G white bars represent 100 mm. In B, D, F and H white bars represent
50 mm.
doi:10.1371/journal.pone.0013164.g003
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development; it protects the organism from deleterious dominant-
negative or gain-of-function effects caused by truncated proteins
translated from stable nonsense transcripts [31,32]. Nagy and
Maquat [33] originally predicted that any premature termination
codon occurring 50 to 55 nucleotides downstream of the 39 most
exon-exon junction of a gene would bypass NMD and further
studies showed that mutations located in different exonic regions
of the same gene may exhibit different NMD responses [34,35].
Since p.R771PfsX33 fulfils the characteristics to escape NMD, we
studied PYGM expression. The levels of PYGM transcripts in the
skeletal muscle of our patients were around 30–40% of those of
controls. This reduction is probably due to NMD, yet of a smaller
Figure 4. Glycogen phosphorylase activity ratio (active/total), glycogen synthase activity ratio (active/total) and glycogen content.
The results represent values for controls (C1, C2) and patients (P1, P2), after 7 days of differentiation. Values are mean 6 SEM. The significance of the
difference versus controls is: *p,0.01 and **p,0.001. Grey bars represent controls and black bars patients.
doi:10.1371/journal.pone.0013164.g004
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magnitude than previously described for other frameshift and
nonsense PYGM mutations, in which transcript levels as low as 1–
5% were observed [12]. Interestingly, PYGM mRNA levels were
similar in our two patients, in agreement with our previous
findings showing more similar PYGM expression levels among
related patients as compared to unrelated patients [12]. Thus,
some unknown factors irrespective of the type of PYGM mutation
could also affect the transcription of the gene or the stability of the
transcript.
In contrast to the presence of substantial PYGM mRNA levels in
patients’ skeletal muscle, this GP isoform was undetectable by
immunoblot in muscle biopsy from P1. This result is consistent
with the absence of GP activity in P1 muscle, and might indicate
an alteration in the translation of mutant mRNA or changes in the
stability of the mutant protein. Translational control is mediated
by regulatory proteins or noncoding RNAs that bind to the 39- or
59- UTR of target mRNAs [36]. The UTR structures can be
missed through disease-causing mutations in coding regions [37],
as previously observed [38]. Similarly, p.R771PfsX33 could be
changing the translation regulation of muscle GP in patients
bearing this mutation.
Pioneer experimental studies have been performed over the last
three decades to obtain and characterize McArdle patients’ muscle
and muscle cell cultures [13,14,15,16,17,39]. These studies
revealed that cultured muscle cells from McArdle patients have
GP activity, even though they are derived from GP-negative
muscle tissue. Interestingly, some regenerative fibres from patients
also ‘‘recover’’ GP activity together with expression of fetal myosin
[17]. Most of these studies were carried out before the PYGM gene
was discovered and when the number of GP isoenzymes was
unknown. This explains, at least partially, the diversity of findings
on GP expression in McArdle muscle cell cultures and the lack of
reports on possible expression of other isoforms. The development
of tools that allow us to distinguish GP mRNA isoforms prompted
us to perform in vitro studies to characterize the GP gene expression
pattern in samples with the p.R771PfsX33 mutation. We only
studied two patients harbouring the same mutation, but we believe
that our results are of interest when considering the scarcity of
available in vitro studies on McArdle’s disease.
PYGM mRNA levels dropped drastically in muscle cell culture
in all differentiation stages, as compared to those observed in
control muscle in vivo. In fact, a transcriptome microarray analysis
has shown that PYGM is among the top downregulated genes in
human cultured myotubes compared to skeletal muscle biopsies
[23]. In contrast, the PYGL messenger was increased in cell
culture, while PYGB mRNA levels were similar to those observed
Figure 5. Electron microscopic analysis of glycogen stores. Electron micrograph of myotubes cultured from (A,C) control C1 and (B,D) patient
P1, at 10 days post-differentiation. Glycogen granules and clusters appear as black dense particles in the cytoplasm. Bar represents 1 mm. Images
were obtained at x 30,000.
doi:10.1371/journal.pone.0013164.g005
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in in vivo muscle. Therefore, the muscular isoenzyme is the only
form that becomes strongly reduced in cell culture, and this
accounts for the strong reduction of GP activity in muscle cultured
cells as compared to muscle tissue previously reported [14,16].
Additionally, the pattern of GP isoforms gene expression changes
in muscle cell cultures along differentiation. This should be taken
into account when cellular models are used for molecular and
biochemical studies in McArdle’s disease. In this regard, using
microarray transcriptional analysis we have previously character-
ized time-dependent changes in the gene expression profile of
cultured human myotubes mostly affecting contractile and
apoptosis-related genes [40].
Immunoblotting experiments did reflect: (i) lower content of the
brain/muscle GP protein in patients’ than controls’ muscle
cultures, (ii) no significant differences but a tendency to increase
when using the specific brain or liver GP antibodies, and (iii) no
signal with the muscle GP-specific antibody in both cultured cell
types, probably because the GP muscle isoform was below
detection level. These data suggest that most of the protein we
detected with the brain/muscle GP antibody corresponded to the
brain isoform, although the lower brain/muscle protein content in
patients may be due to the lack of normal muscle GP protein, as it
occurs in muscle biopsies. Enzyme activity measurements revealed
lower levels of the active form of GP activity and GP activity ratio,
in patients’ cell cultures compared to controls. Nevertheless, total
GP activity was similar in both cell types, in agreement with
previous reports [14,16,39]. GP isoenzymes exhibit differential
regulatory features [41,42]. Our data suggest that the lower levels
of active GP in patients’ cell cultures are not due to the liver
isoenzyme: reduced liver isoenzyme, which is poorly activated by
AMP, would be expected to cause similar decreases in the GP
activity measured without AMP (active) or with AMP (total). This
is not the case: total GP activity levels were comparable between
patients’ and controls’ cultures. Consequently, the reduction
should be due to lower AMP-sensitive muscle or brain GP
isoenzyme activities. In summary, immunoblotting and enzyme
activity data suggest that the reduction in GP protein and activity
in patient’s cultures corresponds to the muscle GP protein isoform.
With regard to the counterpart enzyme in glycogen metabolism,
patients’ cells showed lower levels of the active form of GS activity
and of GS activity ratio, but equivalent total GS activity. Although
GS has not been studied before in McArdle patients’ cell cultures,
previous research performed in vivo in the muscle of McArdle
patients showed similar findings, i.e. preserved total GS activity
levels compared to control subjects, but lower fractional velocity of
GS in the basal condition, at the end of an insulin clamp and after
exercise [43]. Overall these data suggest that GP does somehow
enhance the activation of its opposite counterpart in glycogen
metabolism. In this way, the lack of GP may, as a compensatory
mechanism, contribute to inactivate GS and prevent glycogen
overload in McArdle patients. In line with this hypothesis, in the
patients’ cultures, glycogen content compared to healthy controls’
cultures was similar with a tendency to lower levels, as assessed by
glycogen quantification in cell extracts, and lower number of
glycogen granules with slightly larger diameter, as observed by
electron microscopy. It should be considered that the smaller
difference observed by quantification of glucose following the
isolation and the hydrolysis of muscle cell glycogen may be due to
variations in branch density [44] or glucose contamination [45] of
glycogen or other factors that may affect this technique. Previous
research showed similar glycogen content in McArdle and control
muscle cultures [14]. In vitro data are in contrast to the in vivo
Figure 6. Immunoblotting analysis for brain/muscle GP, brain GP, liver GP and muscle GS proteins, of 7 days differentiated cell
lines. Grey bars represent controls (C1, C2) and black bars patients (P1, P2). Anti-actin immunoblotting was performed as loading control.
Representative images of brain/muscle GP (A), brain GP (B), liver GP (C) and muscle GS (D) are shown. Ratios of intensity of GP (A, B and C) and GS (D)
bands compared to intensity of a-actin bands are shown as mean 6 SEM. The significance of the difference versus controls is *p,0.05.
doi:10.1371/journal.pone.0013164.g006
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findings of abnormal accumulation of glycogen. We hypothesize
that in vivo, the much larger fall in GP activity in patient’s muscle is
likely undercompensated by GS inactivation. More research is
necessary to clarify the GP mechanism of action and metabolic
adaptations that McArdle cultures undergo in the in vitro condition.
No effective gene therapy is expected to be available in the
foreseeable future to replace skeletal muscle GP [6]. Thus, a
deeper knowledge of the regulation and the expression of the
different GP isoforms is necessary, as it could contribute to the
development of new therapeutic approaches for McArdle’s
disease. The re-expression of PYGB or PYGL in skeletal muscle
could restore GP activity in this tissue. The ‘‘proof-of-principle’’ of
such a strategy has been demonstrated by the ability of utrophin to
compensate for the deficiency of dystrophin in the dystrophin-
deficient mouse muscle [46], and by the ability of e-sarcoglycan to
compensate for the lack of a-sarcoglycan in autosomal recessive
limb-girdle muscular dystrophy type-2D [47]. Because distinct GP
isoforms are naturally produced by different tissues within the
same patient, no rejection related problems are to be expected
with this type of ‘re-expression’ therapy. Some problems could
nevertheless arise from the fact that GP isoenzymes can differ in
their regulatory properties and physiological role. Liver GP is
activated in hepatocytes to maintain glucose homeostasis in the
whole body, brain GP is activated in cases of cerebral anoxia and
low glucose availability, whereas muscle GP functions as a glucose
supplier only in working skeletal muscle fibers.
To conclude, we have reported a novel PYGM mutation,
p.R771PfsX33, in two brothers with McArdle’s disease, which
causes reduction in PYGM mRNA, absence of protein and GP
activity. The study of muscle cell cultures from these two patients
and two controls has allowed us to find some clues as to the
puzzling observation of GP-activity positive cultured cells derived
from GP-activity negative muscle biopsy: (1) PYGM mRNA levels
are strongly reduced in muscle cultured cells; (2) differences in the
relative expression of brain and liver GP genes arise during
differentiation in muscle cell culture; (3) most of the GP protein
and activity in cultured muscle cells are brain and liver isoforms;
(4) our data supports the notion that lack of muscle GP in
McArdle’s disease contributes to inactivate GS, thus preventing
glycogen overload in muscle cultured cells.
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